DG's Mr Thiemann has been instrumental in centralising the mutual banks' asset-management, payments and securities businesses, which should boost efficiency and reduce problems at outlying banks.
Dr Thiemann says there are several possible reasons for differences between the new findings and the conventional wisdom, which was based on research trials of clot-busting drugs conducted about a decade ago.